The Necessity of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma Using Antiangiogenic Targeted Therapy After Interferon Alfa-2b

Micro-Abstract The effects of cytoreductive nephrectomy (CRN) on prognosis of patients with metastatic renal cell cancer (RCC) using antiangiogenic targeted agents were evaluated. The median overall survival was significantly higher in the group that received CRN ( P = .034). We speculate that CRN...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical genitourinary cancer 2014-12, Vol.12 (6), p.447-450
Hauptverfasser:	Mutlu, Hasan, Gündüz, Şeyda, Büyükçelik, Abdullah, Yıldız, Özcan, Uysal, Mükremin, Tural, Deniz, Bozcuk, Hakan, Coşkun, Hasan Şenol
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Angiogenesis Inhibitors - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - surgery Combined Modality Therapy Cytoreduction Surgical Procedures Disease-Free Survival Female Hematology, Oncology and Palliative Medicine Humans Interferon-alpha - therapeutic use Kaplan-Meier Estimate Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidney Neoplasms - surgery Male Middle Aged Nephrectomy Prognosis Recombinant Proteins - therapeutic use Renal cell cancer Retrospective Studies Survival Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract The effects of cytoreductive nephrectomy (CRN) on prognosis of patients with metastatic renal cell cancer (RCC) using antiangiogenic targeted agents were evaluated. The median overall survival was significantly higher in the group that received CRN ( P = .034). We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy.
ISSN:	1558-7673 1938-0682
DOI:	10.1016/j.clgc.2014.06.006